menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Shanghai Yingli Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Linperlisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"CS1002","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals Co., Ltd."},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Camrelizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Hengrui Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Hengrui Pharma"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Camrelizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Mycovia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals"},{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"HengRui","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HengRui \/ Hengrui","highestDevelopmentStatusID":"12","companyTruncated":"HengRui \/ Hengrui"},{"orgOrder":0,"company":"HengRui","sponsor":"Hutchmed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HengRui","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"HengRui \/ Hengrui","highestDevelopmentStatusID":"9","companyTruncated":"HengRui \/ Hengrui"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Medicilon","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Hengrui Medicine \/ Jiangsu Hengrui Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Hengrui Medicine

    Menu

    Jiangsu Hengrui Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Medicilon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs

                            Details : Medicilon & Hengrui will collaborate to focus on the preclinical evaluation of new drug modalities such as ADCs, small molecules, etc & to advance the innovation to compete on an international level.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 31, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Medicilon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivoceranib,Camrelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment

                            Details : Aitan (rivoceranib), a VEGFR-2 inhibitor, is being investigated with SHR-1210 (camrelizumab) and is already approved in China. The company has resubmitted its NDA to the FDA for unresectable HCC.

                            Brand Name : Aitan

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : Rivoceranib,Camrelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HengRui

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            HengRui

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib,Camrelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer

                            Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.

                            Brand Name : Sulanda

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 15, 2024

                            Lead Product(s) : Surufatinib,Camrelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HengRui

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            HengRui

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fruquintinib,Sintilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer

                            Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor, playing a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab for endometrial cancer.

                            Brand Name : Fruzaqla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 13, 2024

                            Lead Product(s) : Fruquintinib,Sintilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Hutchmed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Mycovia Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseco...

                            Details : VIVJOA® (oteseconazole) is an azole antifungal and designed to selectively inhibit fungal CYP51, which is indicated for the treatment of severe vulvovaginal candidiasis (VVC).

                            Brand Name : Vivjoa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 21, 2023

                            Lead Product(s) : Oteseconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Mycovia Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rivoceranib,Camrelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as Fir...

                            Details : Apatinib (rivoceranib) is a tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 in combination with AiRuiKa (camrelizumab) a humanized mAb targeting the PD-1 receptor, is being investigated for unresectable hepatocellular carcinoma.

                            Brand Name : Apatinib

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2023

                            Lead Product(s) : Rivoceranib,Camrelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camrelizumab,Rivoceranib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progressi...

                            Details : Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.

                            Brand Name : SHR-1210

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 10, 2022

                            Lead Product(s) : Camrelizumab,Rivoceranib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camrelizumab,Rivoceranib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progr...

                            Details : Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.

                            Brand Name : SHR-1210

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : Camrelizumab,Rivoceranib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CS1002,CS1003

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : CStone Pharmaceuticals

                            Deal Size : $200.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Announce Strategic Partnership and Exclusive Licens...

                            Details : CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.

                            Brand Name : CS1002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 21, 2021

                            Lead Product(s) : CS1002,CS1003

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : CStone Pharmaceuticals

                            Deal Size : $200.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Shanghai Yingli Pharmaceutical

                            Deal Size : $20.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China

                            Details : Yingli Pharma will grant Hengrui Medicine joint development rights and exclusive commercialization rights of PI3kδ inhibitor YY-20394 in Greater China.

                            Brand Name : YY-20394

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 08, 2021

                            Lead Product(s) : Linperlisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Shanghai Yingli Pharmaceutical

                            Deal Size : $20.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth